A Survey of the Available Data on a New Nootropic Drug, BCE‐001

I. Zs.-Nagy
DOI: https://doi.org/10.1111/j.1749-6632.1994.tb12077.x
IF: 6.499
1994-06-01
Annals of the New York Academy of Sciences
Abstract:The nootropic molecule coded BCE-001 (US Patent No. 4661618, 1985)’ was born from a scientific research collaboration between BIOGAL Pharmaceutical Works Ltd. (Debrecen, Hungary) and the Hungarian Section of VILEG, University Medical School (Debrecen, Hungary). The theoretical basis for the design of this new molecule was the membrane hypothesis of aging (MHA). MHA explains cell maturation and aging on the basis of the intrinsic biochemical and physicochemical interactions between the cell plasma membrane and basic oxidative processes of living systems. This working hypothesis has been elaborated since the late seventies;2 it was based on the main achievements of previous experimental gerontological research, such as the cross-linking the free radical theory of aging:.’ and on available knowledge in cell physiology. The MHA has continuously been developed by checking experimentally various points of it in different biological models.&18 MHA was compared to the dysdifferentiation hypothesis of aging and cancer (DHAC), resulting in the conclusion that the two hypotheses are largely complementary to each other.I9 MHA is explained in detail in a recent rnonograph;l8 here we have space only for a short outline of MHA.
What problem does this paper attempt to address?